^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
CLL/SLL without del(17p)/TP53 mutation, First-line therapy, Frail patient with significant comorbidity…Venetoclax + obinutuzumab was changed from a category 2A recommendation to a category 1 recommendation.